Targeting the gatekeeper residue in phosphoinositide 3-kinases
- PMID: 15781393
- DOI: 10.1016/j.bmc.2005.02.021
Targeting the gatekeeper residue in phosphoinositide 3-kinases
Abstract
A single residue in the ATP binding pocket of protein kinases-termed the gatekeeper-has been shown to control sensitivity to a wide range of small molecule inhibitors (Chem. Biol.2004, 11, 691; Chem. Biol.1999, 6, 671). Kinases that possess a small side chain at this position (Thr, Ala, or Gly) are readily targeted by structurally diverse classes of inhibitors, whereas kinases that possess a larger residue at this position are broadly resistant. Recently, lipid kinases of the phosphoinositide 3-kinase (PI3-K) family have become the focus of intense research interest as potential drug targets (Chem. Biol.2003, 10, 207; Curr. Opin. Pharmacol.2003, 3, 426). In this study, we identify the residue that corresponds structurally to the gatekeeper in PI3-Ks, and explore its importance in controlling enzyme activity and small molecule sensitivity. Isoleucine 848 of p110alpha was mutated to alanine and glycine, but the mutated kinase was found to have severely impaired enzymatic activity. A structural bioinformatic comparison of this kinase with its yeast orthologs identified second site mutations that rescued the enzymatic activity of the I848A kinase. To probe the dimensions of the gatekeeper pocket, a focused panel of analogs of the PI3-K inhibitor LY294002 was synthesized and its activity against gatekeeper mutated and wild-type p110alpha was assessed.
Similar articles
-
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.Bioorg Med Chem. 2004 Sep 1;12(17):4749-59. doi: 10.1016/j.bmc.2004.06.022. Bioorg Med Chem. 2004. PMID: 15358300
-
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.Bioorg Med Chem. 2006 Oct 15;14(20):6847-58. doi: 10.1016/j.bmc.2006.06.046. Epub 2006 Jul 11. Bioorg Med Chem. 2006. PMID: 16837202
-
Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.Clin Cancer Res. 2005 Apr 15;11(8):3102-8. doi: 10.1158/1078-0432.CCR-04-1857. Clin Cancer Res. 2005. PMID: 15837766
-
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.
-
Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases.Trends Biochem Sci. 2002 Aug;27(8):426-32. doi: 10.1016/s0968-0004(02)02136-9. Trends Biochem Sci. 2002. PMID: 12151228 Review.
Cited by
-
Targeting protein kinases in central nervous system disorders.Nat Rev Drug Discov. 2009 Nov;8(11):892-909. doi: 10.1038/nrd2999. Nat Rev Drug Discov. 2009. PMID: 19876042 Free PMC article. Review.
-
Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.Commun Biol. 2023 Jun 5;6(1):603. doi: 10.1038/s42003-023-04921-z. Commun Biol. 2023. PMID: 37277510 Free PMC article.
-
Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.J Biol Chem. 2010 Jul 9;285(28):21446-57. doi: 10.1074/jbc.M109.090043. Epub 2010 May 7. J Biol Chem. 2010. PMID: 20452982 Free PMC article.
-
Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae.Cell Rep. 2013 Dec 26;5(6):1725-36. doi: 10.1016/j.celrep.2013.11.040. Epub 2013 Dec 19. Cell Rep. 2013. PMID: 24360963 Free PMC article.
-
Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors.ACS Med Chem Lett. 2020 Nov 19;11(12):2461-2469. doi: 10.1021/acsmedchemlett.0c00441. eCollection 2020 Dec 10. ACS Med Chem Lett. 2020. PMID: 33335668 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
